Navigation Links
Asia Pharm R&D 2010 - New CRO Trends Become Focus of Industry
Date:3/2/2010

SHANGHAI, March 2 /PRNewswire-Asia/ -- Shanghai will welcome Asia Pharm R&D 2010 on March 4-5. This summit will converge local pharmaceutical companies, hospitals, global biotech companies and research institutes and labs in Asia, as well as those from further a field, as well as venture capital firms and consultancies, law firms and even a translation company. Representatives in attendance include those from the U.S., Japan, mainland China, India and Taiwan.

The brainchild of the Global Leaders Institute (GLI) will eventually bring around 150 delegates together with the promise of potential partnering opportunities and helpful workshops, keynote speeches, panel discussions and intriguing company showcases.

The representative from Transhorsa Translation Ltd. (supporter to the whole translation process) describes this event as a milestone in clinical research organisation ("CRO") processes in the global pharmaceutical research chain, especially for Asia's preclinical phase. The main representatives will deliver presentations on Asian strategies: How big pharma and biotech companies manage their R&D activities; How can companies derive maximum value from M&A and licensing deals, diversifying product pipelines; Rethinking about natural products; Exploring biologics; Pros and cons of conducting clinical trials in various Asian countries; How biotech companies can thrive in the prolonged funding drought; and Realizing personalized medicine through translational research; Showcase of novel therapeutics for oncology, cardiology, neurology, inflammation and immunology.

Battered by economic uncertainty and under pressure to deliver better medical products in more cost-effective ways, pharmaceutical companies are increasingly driven to outsource their research and development to CROs in Asia.

This trend in the biomedical sector is poised to make China one of the most popular CRO destinations within the next 10 years. This week, RightSite looks at how investors can profit from the growth of China's CRO industry. With the rapid outsourcing development from pharmaceutical research to clinical trial, China's progress on the protection of pharmaceutical IP rights offers a better investment environment for multinational pharmaceuticals that sow millions of dollars every year into R&D. The State Food and Drug Administration (SFDA) Law of China was revised in 2000 to allow the patenting of pharmaceutical compositions, which established a major improvement over the previous practice of only allowing the patenting of a method to make or use a drug.

According to research published by Australian law firm DLA Phillips Fox, China has put new measures in place to raise the penalties for patent infringement from 300% to 400% of illicit profits and increasing damage payments from RMB 50,000 to RMB 200,000, even if there is no profit from the infringement. These changes are just part of the changing attitudes towards protecting patents and other intellectual property that is making China more attractive for research dependent industries such as CROs.

"China's returnees abundant human capital, lower business costs and experienced returnees (nicknamed "seaturtles" in China) is allowing entrepreneurs to build Chinese biotech firms that are far more integrated -- with significant capabilities in disciplines ranging from discovery research through clinical development -- than their counterparts in the west. And this integrated approach can produce more efficient and productive R&D," described Samantha Du, Ph.D. Chief Executive Officer, Hutchison MediPharma Limited.

Trends in pharmaceutical development is an area organizations are most concerned with, and Greg Wiederrech PhD, Vice President & Head from Merck & Co., will present Driving Innovation through Strategic Relationships at the Summit, "Pipeline woes throughout the pharma industry are well acknowledged and executives are responding via a number of strategic actions including mergers, acquisitions, entries into other modalities such as biologics and siRNA, entries into new geographic markets, regional deal making, and more risk sharing. Some of these strategies will win and some may not."

Chunlin Chen PhD of Shanghai Medicilon Inc, said, "Many CROs emerged in China to offer customers cost-effective synthetic capabilities as well as aid with molecular design and preclinical services. Currently, more and more international and domestic pharmaceutical companies are seeking integrated services CROs for their R&D work." He will state different collaboration patterns between integrated services CROs and pharmaceutical companies that he has assumed with many case studies in practice and ahead of the development.

Regarding the current financial downturn, Fintan Walton PhD, Chief Executive and Founder, PharmaVentures UK appears to have a positive outlook as "pharma companies, biotech and startups, when looking to China and Asia to conduct R&D more efficiently, tap into local centres of expertise, and options for funding in the region are becoming increasingly diverse against a backdrop of a global biotech funding downturn" like OBN's press release statement "Biotech Investment is Safer than Banks."

The summit will make a successful round of presentations and a large number of private partnering discussions occurring throughout the two days, GLI will push pharmaceutical and preclinical research far more than ever before.

At the heart of the financial and business district in Shanghai, the beautiful InterContinental Hotels & Resorts will be the base for this summit, and private business meetings and one-on-one networking sessions are going to ensure Asia Pharm R&D 2010 can create a more efficient and effective way for contributors of this field to communicate and improve their projects to success.

    For more information, please contact:

     Monica Sun
     Tel:   +86-10-5900-0971 x607
     Email: Monica.sun@globaleaders.com

SOURCE Global Leaders Institute

Back to top
'/>"/>
SOURCE Global Leaders Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Emergency Physician and ... of the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Emergency Medicine at the University of Arizona College of Medicine. He also serves as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree ... fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor ... as little as $14,528. These changes will enable nurses to complete their degree in ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier ... position. The former overall number one pick in the 2001 NFL Draft, to the ... the record for the most career rushing yards by a quarterback (6,109) and the ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
(Date:4/18/2017)... Mass. , April 18, 2017  Spero Therapeutics, ... for the treatment of bacterial infections, will present preclinical ... the treatment of multidrug resistant (MDR) Gram-negative infections at ... Diseases (ECCMID) April 22-25, 2017 in Vienna, ... ...
Breaking Medicine Technology: